The JAK2 V617F Mutation in a Patient with Acute Myeloid Leukemia: a Case Report and Literature Review

Acute myeloid leukemia (AML) is a malignant clonal disease of hematopoietic stem cells. It can also be secondary to other blood system diseases such as myelodysplastic syndromes (MDS) and myeloproliferative tumors neoplasms (MPN). The JAK2 V617F mutation has been reported in MPN, but rarely reported in patients with AML. This report is related a 60-year-old patient who suffered from AML with JAK2 V617F mutation. The platelet count was 603 × 109/L at onset. He was given the DA regimen for induction chemotherapy and received complete remission. But the regimen was forced to stop due to acute cerebral infarction after second HDA regimen consolidation chemotherapy. Six months later, the patient had a recurrence. No complete remission was achieved after repeated chemotherapy. At the same time, the patient was given aspirin for antiplatelet aggregation and interferon to reduce platelets, but he stopped using interferon because of the severe infection. Later the patient presented with acute cerebral infarction again. This is a rare case report indicating that the patient with JAK2 V617F mutation had a poor prognosis and had recurrent thrombotic diseases because of elevated platelets. Figure 1: Bone marrow morphology in January 21, 2015 (He × 1000). Citation: Li J, Wang H (2017) The JAK2 V617F Mutation in a Patient with Acute Myeloid Leukemia: a Case Report and Literature Review. J Blood Lymph 7: 177. doi: 10.4172/2165-7831.1000177